Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins

This study has been completed.
Information provided by (Responsible Party):
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Identifier:
First received: September 13, 2005
Last updated: July 30, 2015
Last verified: July 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2005
  Primary Completion Date: July 2005 (Final data collection date for primary outcome measure)